Previous 10 | Next 10 |
The following slide deck was published by Cellectis S.A. in conjunction with this Read more ...
Cellectics (CLLS) finds itself in a period of long-term consolidation after a period of sustained downtrend resulting from a 1-2-3-4-5 downside impulse wave from 2018. This analysis piece features insight as to the expected pattern of price movement that will be seen as we head into the 2 nd ...
Cellectis (NASDAQ: CLLS ): Q1 GAAP EPS of -$0.26 beats by $0.40 . More news on: Cellectis S.A., Earnings news and commentary, Healthcare stocks news, Read more ...
- Started construction of in-house manufacturing facilities IMPACT and SMART - FDA approved IND for UCARTCS1A product candidate in Multiple Myeloma - Published novel manufacturing methods to improve allogeneic CAR T-cell safety and purity - Cash position 1 of $425 millio...
Noteworthy events during the week of April 28 - May 4 for healthcare investors. More news on: Catalyst Biosciences, Inc., Aldeyra Therapeutics, Inc., BioTime, Inc., Healthcare stocks news, , Read more ...
- Oral presentation to include preclinical UCARTCS1A data in Multiple Myeloma - Poster presentation to focus on improved manufacturing for allogeneic CAR T-cells Regulatory News: Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical compa...
Successful manufacturing and release of GMP vials of UCARTCS1 Regulatory News: Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), announced today that the U.S. Fo...
The following slide deck was published by Cellectis S.A. in conjunction with this Read more ...
The following slide deck was published by Cellectis S.A. in conjunction with this Read more ...
Cellectis (NASDAQ: CLLS ): Q4 GAAP EPS of -$0.53. More news on: Cellectis S.A., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...